Quantcast

Latest Therapies under investigation for multiple sclerosis Stories

7d6c5e2a2a65ac0a0e019d7364038c9d1
2008-12-15 14:42:08

On Monday, Biogen Idec Inc said it notified regulators of a new case of a potentially deadly brain disease in a patient being treated with its Tysabri multiple sclerosis drug, the fourth such case reported globally this year.

2008-10-28 12:00:39

CAMBRIDGE, Mass., Oct. 28 /PRNewswire/ -- Peptimmune, Inc., a privately held biotechnology company, announced today that President & CEO Thomas P.

2008-10-24 09:00:26

Opexa Therapeutics, a biopharmaceutical company, has announced additional positive data from the company's Phase IIb clinical trial for the treatment of multiple sclerosis.

2008-10-23 18:00:09

Biogen Idec (NASDAQ: BIIB) today announced the publication of Phase IIb data showing that a 240 mg three-times-daily dose of the company's novel oral compound, BG-12 (BG00012, dimethyl fumarate), reduced the number of new gadolinium enhancing (Gd+) lesions by 69 percent in patients with relapsing-remitting

69f96049fb2993a4f81399f887bdfe8d1
2008-10-23 15:56:08

A drug developed for patients with leukemia also appears to regenerate brain cells and reverse the effects of relapsing-remitting multiple sclerosis, British researchers said on Wednesday.

2008-10-23 06:00:27

By Rita Rubin A leukemia drug was about 70% more effective than a standard therapy in treating early multiple sclerosis, according to clinical trial results in today's New England Journal of Medicine.

2008-10-07 09:00:55

Genentech and Biogen Idec have announced that a global Phase III study of Rituxan in combination with fludarabine and cyclophosphamide chemotherapy met its primary endpoint of improving progression-free survival, as assessed by investigators, in patients with previously treated CD20-positive chronic lymphocytic leukemia compared to chemotherapy alone.

2008-09-24 12:00:37

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has announced that the ongoing Improve study met its primary endpoint.

2008-09-22 12:00:38

Opexa Therapeutics has announced top-line data from the company's Phase IIb Tovaxin for early relapsing multiple sclerosis, or Terms, study.

2008-09-22 00:00:27

MELBOURNE, Australia and CARLSBAD, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Antisense Therapeutics Ltd. and Isis Pharmaceuticals, Inc.


Word of the Day
logocentrism
  • The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.
The word 'logocentrism' is a blend of logo- +‎ centrism.
Related